HUBEI DINGLONG CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.19 CNY | -0.98% |
|
-2.11% | -4.17% |
| Apr. 25 | Hubei Dinglong CO.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 11 | Nomura Adjusts Hubei Dinglong’s Price Target to 24 Yuan From 22 Yuan, Keeps at Buy | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 50.99 and 36.39 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.17% | 3.01B | - | ||
| +17.73% | 66.69B | A- | ||
| +16.33% | 41.24B | B+ | ||
| +20.03% | 25.89B | A- | ||
| +12.78% | 19.81B | C+ | ||
| +0.85% | 17.11B | B+ | ||
| -21.87% | 15.86B | A- | ||
| +2.32% | 15.35B | B+ | ||
| -10.29% | 15.23B | C+ | ||
| -22.30% | 13.36B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300054 Stock
- Ratings Hubei Dinglong CO.,Ltd.
